Skip to main content

Table 2 Characteristics of patients

From: Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis

Characteristic Category Type of tumor Total
Solid Hematological Both
Enrolled patients, n   559 491 152 1202
Evaluated patients, n (%)   524 (93.7) 470 (95.7) 151 (99.3) 1145 (95.3)
Male, n (%)a   290 (51.9) 214 (43.6) 80 (52.6) 584 (48.6)
Median age at enrollment, n (%) of studiesb, years < 6 0 (0) 0 (0) 0 (0) 0 (0)
6.0–11.9 9 (40.9) 3 (33.3) 2 (66.7) 14 (41.2)
12.0–17.9 8 (36.4) 3 (33.3) 0 (0) 11 (32.4)
18–21 2 (9.1) 1 (11.1) 0 (0) 3 (8.8)
Performance status scale used, n (%) of studies Lansky/Karnofsky scale 16 (72.7) 4 (44.4) 1 (33.3) 21 (61.8)
ECOG/WHO/Zubrod 1 (4.6) 1 (11.2d) 0 (0) 2 (5.9)
Both 4 (18.1d) 2 (22.2) 1 (33.3) 7 (20.6)
Otherc 0 (0) 0 (0) 1 (33.4d) 1 (2.9)
Not reported 1 (4.6) 2 (22.2) 0 (0) 3 (8.8)
  1. ECOG Eastern Cooperative Oncology Group, WHO World Health Organization
  2. aSex was not reported in 1 mixed malignancy, 2 solid tumor, and 3 hematological malignancy studies
  3. bAge was not reported in 1 mixed malignancy, 3 solid tumor, and 2 hematological malignancy studies
  4. cOther: Lansky/Karnofsky scale plus Standard Children’s Oncology Group criteria for performance status
  5. dPercentage was calculated by subtracting the remaining % values from 100%